CVS is an online drugstore and pharmacy that provides prescription services, health information, and wellness products. Self-described as a provider of health and wellness solutions.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Robert Walter

Cardinal Health, Inc.

Collective Health is a healthcare technology company that aims to simplify and improve the healthcare experience for individuals and organizations. They provide a platform that brings together various healthcare solutions to create a more coordinated, connected, and seamless healthcare experience.

Metric
Company Name	CVS	AstraZeneca PLC	Cardinal Health, Inc.	Collective Health
Symbol		AZN	CAH
MSH ID	COM:CVS	COM:ASTRAZENECA	COM:CARDINALHEALTH	COM:COLLECTIVEHEALTH
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Pharmacy and Retail Health	Drug Manufacturers - General	Medical - Distribution	Healthcare Technology
Country	US	GB	US
Stage
Employee Count		89.90K	47.04K	501
Website	cvs.com	astrazeneca.com	cardinalhealth.com	collectivehealth.com
LinkedIn		astrazeneca
Founders

Metric
Market Cap	2.39B	23.28B
Enterprise Value
Monthly Web Traffic	758.60K
Web Traffic Growth	-0.13
Valuation
Raised Capital

Metric
Revenue	45.81B	226.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	37.54B	7.41B
EBITDA	13.91B	1.24B
Operating Income	8.19B	1.24B
Net Income	5.96B	852M
EPS	3.84	3.48
Diluted EPS	3.81	3.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.82	0.03
Operating Profit Margin	0.19	0.01
EBITDA Margin	0.30	0.01
Net Profit Margin	0.13	0.00
Return on Equity	0.17	-0.17
Return on Assets	0.06	0.02
Return on Capital Employed	0.12	0.17

CVS

COM:CVS

CVS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	34.12	39.78
P/B Ratio	5.41	-7.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.51	0.13
EV Multiple	16.93	9.86

Metric
Days Sales Outstanding		19.91
Days Payables Outstanding	846.26	59.85
Days Inventory Outstanding	239.45	32.24
Operating Cycle	317.44	52.14
Cash Conversion Cycle	95.22	-6.21
Asset Turnover	0.47	5.03

Metric
Operating Cash Flow	10.35B	3.76B
Free Cash Flow	6.57B	3.25B
Cash Flow to Debt	0.36	0.84
Operating Cash Flow/Sales	0.23	0.02
Free Cash Flow Yield	0.03	0.13

Metric
Cash & Equivalents	5.84B	5.13B
Accounts Receivable		-996M
Inventory	5.42B	14.96B
Goodwill	20.05B
Debt to Capitalization	0.48	3.71
Debt to Assets	0.30	0.10
Current Ratio	0.79	0.98
Quick Ratio	0.70	0.56

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.00
R&D to Revenue	0.23
SG&A to Revenue